Educational Media
Mechanism of Action
Expert Perspectives
Promising Anatomic Outcomes from the LIGHTSITE III Trial
Diana V. Do, MD, and Glenn J. Jaffe, MD
Diana V. Do, MD, and Glenn J. Jaffe, MD, discuss key anatomic findings from the LIGHTSITE III clinical trial evaluating photobiomodulation (PBM) with the FDA-authorized Valeda® Light Delivery System (LumiThera, Inc.) to treat dry age-related macular degeneration (AMD). Drs. Do and Jaffe share their observations of the data, citing a decrease in the proportion of eyes that developed geographic atrophy and a reduction of drusen volume.
Valeda Demonstrates Vision Improvement in Patients with Dry AMD
Diana V. Do, MD, and Glenn J. Jaffe, MD
Diana V. Do, MD, and Glenn J. Jaffe, MD, discuss the efficacy and safety outcomes from the LIGHTSITE III clinical trial evaluating the Valeda® Light Delivery System for the treatment of dry age-related macular degeneration (AMD). Dr. Do shares key results from the study, emphasizing how the trial successfully met its primary visual acuity endpoints. Valeda® Light Delivery System is FDA-Authorized, CE-Marked, UKCA-Marked, and commercially available in select countries across Latin America.
Safety and Efficacy Results from LIGHTSITE III Trial for Dry AMD
David S. Boyer, MD; and Marion R. Munk, MD, PhD
David S. Boyer, MD, and Marion R. Munk, MD, PhD, discuss pivotal findings from the LIGHTSITE III clinical trial in patients with dry age-related macular degeneration (AMD). Dr. Boyer underscores the potential of this innovative treatment to deliver meaningful clinical benefits, emphasizing its favorable safety profile. Dr. Munk offers a comprehensive review of the study design and parameters, providing valuable context and interpretation of the trial’s outcomes. Valeda® Light Delivery System is FDA-Authorized, CE-Marked, UKCA-Marked, and commercially available in select countries across Latin America.
Month 24 Clinical Trial Results in Dry AMD Patients
Eleonora Lad, MD, and Victor Gonzalez, MD
Eleonora, MD, and Victor Gonzalez, MD, discuss key outcomes from the LIGHTSITE III clinical trial evaluating photobiomodulation therapy with the Valeda® Light Delivery System. Dr. Lad highlights that the study met its primary endpoint, showing a statistically significant improvement in BCVA. Dr. Gonzalez emphasizes the reduction in new geographic atrophy development, suggesting Valeda’s potential in managing dry AMD as a chronic, progressive disease.
